Western blot (WB) analysis with primary antibody against CgA validated by both immunoblotting and immunohistochemistry (IHC) revealed a significant increase of CgA protein levels in Braak stage VI AD patient frontal cortex and hippocampal lysates compared to Braak stage 0-II (Patient Sample details mentioned in Supplementary Table 1), correlated with higher levels of pathogenic Tau phosphorylation (p-Tau, S202/T205) (Fig. 1A–D, S-Fig. 1A–C). The gene discussed is MAPT; the disease is Alzheimer disease.